Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Longitudinal analysis of antibody cross-neutralization following zika virus and dengue virus infection in Asia and the Americas
Authors: Magelda Montoya
Matthew Collins
Wanwisa Dejnirattisai
Leah C. Katzelnick
Henry Puerta-Guardo
Ramesh Jadi
Samuel Schildhauer
Piyada Supasa
Sirijitt Vasanawathana
Prida Malasit
Juthathip Mongkolsapaya
Aruna D. De Silva
Hasitha Tissera
Angel Balmaseda
Gavin Screaton
Aravinda M. De Silva
Eva Harris
Ministry of Health Colombo
University of Colombo Faculty of Medicine
University of Oxford
University of California, Berkeley
University of North Carolina School of Medicine
Imperial College London
Khon Kaen Regional Hospital
Thailand National Center for Genetic Engineering and Biotechnology
Faculty of Medicine, Siriraj Hospital, Mahidol University
Genetech Research Institute
Ministry of Health
Keywords: Medicine
Issue Date: 13-Jul-2018
Citation: Journal of Infectious Diseases. Vol.218, No.4 (2018), 536-545
Abstract: © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. Background The 4 dengue virus serotypes (DENV1-4) and Zika virus (ZIKV) are related mosquito-borne flaviviruses of major importance globally. While monoclonal antibodies and plasma from DENV-immune donors can neutralize or enhance ZIKV in vitro and in small-animal models, and vice versa, the extent, duration, and significance of cross-reactivity in humans remains unknown, particularly in flavivirus-endemic regions. Methods We studied neutralizing antibodies to ZIKV and DENV1-4 in longitudinal serologic specimens collected through 3 years after infection from people in Latin America and Asia with laboratory-confirmed DENV infections. We also evaluated neutralizing antibodies to ZIKV and DENV1-4 in patients with Zika through 6 months after infection. Results In patients with Zika, the highest neutralizing antibody titers were to ZIKV, with low-level cross-reactivity to DENV1-4 that was greater in DENV-immune individuals. We found that, in primary and secondary DENV infections, neutralizing antibody titers to ZIKV were markedly lower than to the infecting DENV and heterologous DENV serotypes. Cross-neutralization was greatest in early convalescence, then ZIKV neutralization decreased, remaining at low levels over time. Conclusions Patterns of antibody cross-neutralization suggest that ZIKV lies outside the DENV serocomplex. Neutralizing antibody titers can distinguish ZIKV from DENV infections when all viruses are analyzed simultaneously. These findings have implications for understanding natural immunity and vaccines.
ISSN: 15376613
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.